Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-24T01:40:49.347Z Has data issue: false hasContentIssue false
  • English
  • Français

Associations of neuroinflammatory parameters with clinical features in patients with mild cognitive impairment and dementia

Published online by Cambridge University Press:  01 September 2022

Y. Zorkina ,
T. Syunyakov ,
A. Andriushchenko ,
O. Abramova ,
M. Kurmishev ,
G. Kostyuk  and
A. Morozova
Y. Zorkina*
Affiliation:
V.P. Serbsky National Medical Research Center for Psychiatry and Narcology, Department Of Basic And Applied Neurobiology, Moscow, Russian Federation Mental Health Clinic No. 1 named after N. A. Alexeev, Research Center, Moscow, Russian Federation
T. Syunyakov
Affiliation:
Mental Health Clinic No. 1 named after N. A. Alexeev, Research Center, Moscow, Russian Federation
A. Andriushchenko
Affiliation:
Mental Health Clinic No. 1 named after N. A. Alexeev, Research Center, Moscow, Russian Federation
O. Abramova
Affiliation:
V.P. Serbsky National Medical Research Center for Psychiatry and Narcology, Department Of Basic And Applied Neurobiology, Moscow, Russian Federation
M. Kurmishev
Affiliation:
Mental Health Clinic No. 1 named after N. A. Alexeev, Research Center, Moscow, Russian Federation
G. Kostyuk
Affiliation:
Mental Health Clinic No. 1 named after N. A. Alexeev, Research Center, Moscow, Russian Federation
A. Morozova
Affiliation:
V.P. Serbsky National Medical Research Center for Psychiatry and Narcology, Department Of Basic And Applied Neurobiology, Moscow, Russian Federation Mental Health Clinic No. 1 named after N. A. Alexeev, Research Center, Moscow, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Mild cognitive impairment (MCI) represent a state of cognitive function between normal aging and dementia and does not always progress to dementia. Neuroinflammation has a key role in the pathogenesis of neurodegeneration. Determining the associations of neuroinflammatory markers in the blood with clinical disease severity may be useful for early diagnosis of cognitive impairment and prediction of the development of severe dementia.

Objectives

The aim of our study was to compare the serum concentration of a panel of inflammatory markers in patients with MCI and dementia as well as their associations with clinical symptoms.

Methods

Patients were evaluated using Mini-Mental State Examination (MMSE), Clock Drawing Test (CDT), Montreal Cognitive Assessment scales (MoCA), Clinical Dementia rating (CDR) and Hospital Anxiety Depression Scale (HADS). We determined the serum concentration of a panel of inflammatory markers (25 units) cytokines, chemokines, growth factors and several others on Mulliplex and prepared multivariate analysis to investigate associations between clinical features and serum concentration.

Results

Patients with dementia had lower scores on scales than the control and MCI groups. MCI patients were equal to the control group, except for the MMSE scale. EGF, eotaxin-1, GRO-α, IP-10, IL-8, MIP-1β, sCD40L, TNF-α, MDC and MCP-1, VEGF were differ between groups. Multivariate analysis identified some neuroinflammatory parameters associated with the severity of the disease.

Conclusions

We identified some neuroinflammatory parameters associated with dementia and MCI. Many of them have been poor described and data is contradictory. It is necessary to investigate these parameters as potential biomarkers of neurodegeneration in further studies.

Disclosure

No significant relationships.

Keywords

MoCAMCIMMSEDementia
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S172
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.